BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/27/2023 5:08:21 PM | Browse: 525 | Download: 1564
Publication Name World Journal of Gastroenterology
Manuscript ID 87732
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Retrospective Study
Article Title Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study
Manuscript Source Unsolicited Manuscript
All Author List Wen-Ting Peng, Chuan Jiang, Fei-Lan Yang, Nian-Qi Zhou, Ke-Yu Chen, Jin-Qing Liu, Shi-Fang Peng and Lei Fu
ORCID
Author(s) ORCID Number
Wen-Ting Peng http://orcid.org/0000-0002-9072-1332
Chuan Jiang http://orcid.org/0000-0003-2022-5242
Shi-Fang Peng http://orcid.org/0000-0003-4229-0299
Lei Fu http://orcid.org/0000-0001-7550-1254
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China No. 82170640, and No. 81974080
Natural Science Foundation of Hunan Province No. 2022JJ30954
Corresponding Author Lei Fu, MD, Professor, Department of Infectious Diseases, Xiangya Hospital Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. fulei92@126.com
Key Words Alanine transaminase normalization; Chronic hepatitis B; Renal safety; Virological response; Blood lipid; Tenofovir
Core Tip This is a retrospective study to compare the efficacy and safety of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) for 48 wk in patients with chronic hepatitis B (CHB). Our study found that TMF is as effective as TAF in treating CHB and has comparable safety profiles. In addition, TAF may cause deterioration of lipid profiles. These results suggest that TMF may be a viable alternative to TAF for CHB treatment.
Publish Date 2023-11-27 17:08
Citation Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, Peng SF, Fu L. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol 2023; 29(44): 5907-5918
URL https://www.wjgnet.com/1007-9327/full/v29/i44/5907.htm
DOI https://dx.doi.org/10.3748/wjg.v29.i44.5907
Full Article (PDF) WJG-29-5907-with-cover.pdf
Full Article (Word) WJG-29-5907.docx